⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2025Open Access

Supplementary FIgure S7 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer

Tony Georgiev Sara Puglioli Lucrezia Principi Ettore Gilardoni Christian Pellegrino Gabriele Bassi Andrea Galbiati Dario Neri Samuele Cazzamalli

View Full Paper

Ask AI

Bookmark

Share

Key Points

Promising drug conjugates show potential effectiveness against prostate cancer, highlighting advances in treatment options.
The use of a peptidase-cleavable linker enhances the specificity of the drug conjugates in targeting cancer cells.
Chromatographic analysis reveals detailed characteristics of the drug, indicating its suitability for further investigation.
Continued research may enable improved therapies for prostate cancer, addressing current treatment limitations.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Observational analysis shows promising drug conjugates for prostate cancer, suggesting new therapeutic avenues.

Abstract

LC chromatogram of I7

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Georgiev et al. (2025) studied this question.

synapsesocial.com/papers/68e040f7a99c246f578b3bf5 https://doi.org/10.1158/1535-7163.30255263

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S8 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
2Supplementary Figure S1 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
3Supplementary Figure S6 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
4Supplementary Figure S5 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
5Supplementary Figure S2 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025

More related papers

Supplementary Figure S4 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
Supplementary Figure S3 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
Supplementary Figure S14 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025